納微科技(688690.SH)：擬收購參股公司賽譜儀器43.9621%股權
格隆匯4月11日丨納微科技(688690.SH)公佈，公司擬以現金方式收購參股公司蘇州賽譜儀器有限公司(“賽譜儀器”)43.9621%股權，收購對價為人民幣11320.24萬元。
此次股權收購完成後，公司合計持有賽譜儀器953.9880萬元出資，佔賽譜儀器註冊資本的76.6664%，賽譜儀器將成為公司的控股子公司。
公吿顯示，賽譜儀器是一家主要從事蛋白純化系統研發、生產和銷售的高新技術企業，截至目前已推出SCG系列、SCG-P系列、SDL系列等用於大分子分離純化的產品以及Relianx系列等用於小分子分析純化的產品。賽譜儀器的主要客户羣體包括高校和科研院所、生物製藥企業、CRO/CDMO公司和生物技術/診斷技術公司等；賽譜儀器始終重視研發和技術創新，曾承擔江蘇省科技計劃項目“一種全自動蛋白純化層析系統”的研發任務。
賽譜儀器的產品優勢包括：(1)功能專業化，配套了比較完善的軟件和檢驗檢測方法，中英文雙語切換功能方便客户使用；(2)產品優質化，純化系統產品的元部件技術性能指標好，多與國際優質供應商開展合作；(3)耗材一體化，可以與公司的填料耗材配套生產，為客户提供設備、耗材、工藝和人員培訓的綜合服務；(4)生產本土化，以高性價比的產品和技術服務贏得客户，且客户服務響應速度較快。
此外，賽譜儀器還設有1家全資子公司蘇州賽譜科技儀器有限公司，以及2家分公司蘇州賽譜儀器有限公司廣州分公司和蘇州賽譜儀器有限公司北京分公司。
公司色譜填料/層析介質與賽譜儀器蛋白分離純化系統的主要客户均為生物製藥企業和研發機構，因而在客户拓展和市場銷售過程中可實現較好的協同效應。通過將賽譜儀器納入合併報表範圍，公司可充分發揮自身及賽譜儀器技術優勢，進一步優化、整合和共享雙方在核心技術、客户資源和渠道資源方面的積累，增強全產業鏈覆蓋和服務能力，為客户提供包括材料、耗材和儀器設備在內的一攬子解決方案，幫助其更好地建立、完善和優化蛋白純化工藝，推動色譜填料/層析介質及蛋白純化系統產品在各自存量客户中的銷售，藉助協同效應擴大整體業務規模，實現“1+1>2”的良性發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
